onc Videos

Videos

Videos

Targeted Therapies for MET-Dependent Lung Cancers

09/26/2023

Featuring Natasha Leighl, MD

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, discussed advances in targeted therapies for patients with MET-dependent lung cancers.

At the Great Debates & Updates...

09/26/2023

Oncology

Videos

Primacy of Front-Line Checkpoint Inhibitors in Non-Small Cell Lung Cancer

09/26/2023

Featuring Natasha Leighl, MD, FRCPC, FASCO

Featuring Natasha Leighl, MD, FRCPC, ...

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, FRCPC, FASCO, discussed the primacy of front-line checkpoint inhibitors in non-small cell lung cancer.

At the Great Debates & Updates...

09/26/2023

Oncology

Videos

Challenges and Opportunities of Biomarker Diagnostics in Lung Cancer

09/23/2023

Featuring Ignacio Wistuba, MD

At Great Debates & Updates in Lung Cancer, Ignacio Wistuba, MD, discussed the challenges and opportunities associated with biomarker diagnostics in lung cancer.

At Great Debates & Updates in...

09/23/2023

Oncology

Videos

RET, NTRK, NRG1, and ROS1 Fusions as Targets in Lung Cancer

09/23/2023

Featuring Deborah Doroshow, MD, PhD

Featuring Deborah Doroshow, MD, PhD ...

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.

At the Great Debates & Updates...

09/23/2023

Oncology

Videos

Evaluating Advances in the Treatment Landscape for Patients With Follicular Lymphoma

09/22/2023

Featuring Matthew Matasar, MD

Matthew Matasar, MD, discusses upcoming studies and encouraging advances in the evolving treatment landscape for patients with follicular lymphoma.

Matthew Matasar, MD, discusses...

09/22/2023

Oncology

Videos

The Case for Alectinib in ALK-Positive NSCLC

09/22/2023

Featuring Ticiana Leal, MD

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Ticiana Leal, MD, debated in favor of alectinib over lorlatinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).

At the Great Debates & Updates...

09/22/2023

Oncology

Videos

Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL

09/22/2023

Featuring Kami J. Maddocks, MD

Featuring Kami J. Maddocks, MD ...

Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.

Kami J. Maddocks, MD, discusses...

09/22/2023

Oncology

Andrea Casadei-Gardini, MD, San Raffaele Research Hospital

Videos

Real-World Efficacy and Safety of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer

09/22/2023

Featuring Andrea Casadei-Gardini, MD

Featuring Andrea Casadei-Gardini, MD ...

A real-world analysis of durvalumab plus gemcitabine-cisplatin confirmed the results seen in previous clinical trials, supporting the use of this combination in clinical practice.

A real-world analysis of...

09/22/2023

Oncology

Videos

Exploring the Role of FGFR1 as a Therapeutic Target Among Patients With MCL

09/22/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...

Narendranath Epperla, MD, MS, discusses the current research on fibroblast growth factor receptor-1 as an up-and-coming and viable therapeutic target for patients with mantle cell lymphoma.

Narendranath Epperla, MD, MS,...

09/22/2023

Oncology

Videos

Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma

09/22/2023

Featuring Matthew Matasar, MD

Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, shares...

09/22/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology